Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER Benefit/Risk Assessment Tool Has Room For OTC Considerations

This article was originally published in The Tan Sheet

Executive Summary

A new benefit/risk framework for drug reviews currently being tested in FDA requires incremental considerations to apply to OTC reviews, a CDER official says. Former NDAC chairman Brass says FDA’s model is compatible with a separate OTC assessment framework developed for industry.

Advertisement

Related Content

Some OTC Switch Benefits Are Intangible, But Influential – CDER’s Ganley
Some OTC Switch Benefits Are Intangible, But Influential – CDER’s Ganley
Intangible Benefits Are Influential In OTC Switch Decisions – CDER’s Ganley
Intangible Benefits Are Influential In OTC Switch Decisions – CDER’s Ganley
Oxytrol Switch Showcases FDA’s New Benefit-Risk Framework – Soller
Oxytrol Switch Showcases FDA’s New Benefit-Risk Framework – Soller
Risk/Benefit Value Tool Could Trim Guesswork From OTC Switch Attempts

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105769

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel